Benzinga · Feb 18, 2026
HI
NASDAQ · HIND
Vyome Holdings, Inc.
Healthcare · Biotechnology
$2.24
Down-$0.05 (-2.10%)
Updated Aug 25, 2026, 12:11 PM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 27.41M
- P/E ratio
- -0.12
- Dividend yield
- 0.00%
- 52-week range
- $1.75 – $12.00
- Volume
- 3.67K
- Avg. volume
- 321.94K
Price performance
HIND price history
1M range · 21 trading sessions · Daily adjusted prices
HIND closed at $2.24 after 21 trading sessions, up 12.10% for the selected period.
- Last close
- $2.24
- Period change
- +12.10%
- Period low
- $1.99
- Period high
- $2.32
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 24, 2026 | $2.19 | $2.2999 | $2.19 | $2.242 | 3.67K |
| Aug 21, 2026 | $2.21 | $2.30 | $2.21 | $2.25 | 4.69K |
| Aug 20, 2026 | $2.28 | $2.32 | $2.225 | $2.28 | 9.49K |
| Aug 19, 2026 | $2.1993 | $2.3593 | $2.1993 | $2.32 | 25.4K |
| Aug 18, 2026 | $2.2241 | $2.27 | $2.1386 | $2.2699 | 6.66K |
| Aug 17, 2026 | $2.13 | $2.30 | $2.13 | $2.27 | 14.41K |
| Aug 14, 2026 | $2.17 | $2.23 | $2.12 | $2.18 | 6.14K |
| Aug 13, 2026 | $2.18 | $2.24 | $2.13 | $2.16 | 5.41K |
| Aug 12, 2026 | $2.26 | $2.26 | $2.22 | $2.22 | 11.49K |
| Aug 11, 2026 | $2.2357 | $2.2744 | $2.2301 | $2.25 | 9.08K |
| Aug 10, 2026 | $2.16 | $2.22 | $2.1304 | $2.21 | 6.26K |
| Aug 7, 2026 | $2.10 | $2.16 | $1.99 | $2.16 | 15.22K |
| Aug 6, 2026 | $2.135 | $2.14 | $2.13 | $2.14 | 1.91K |
| Aug 5, 2026 | $2.17 | $2.27 | $2.125 | $2.14 | 10.17K |
| Aug 4, 2026 | $2.18 | $2.20 | $2.10 | $2.17 | 5.91K |
| Aug 3, 2026 | $2.09 | $2.18 | $1.9701 | $2.165 | 11.05K |
| Jul 31, 2026 | $2.03 | $2.1394 | $2.01 | $2.115 | 23.25K |
| Jul 30, 2026 | $2.0525 | $2.0525 | $2.00 | $2.01 | 2.45K |
| Jul 29, 2026 | $1.99 | $2.07 | $1.98 | $1.99 | 5.36K |
| Jul 28, 2026 | $2.03 | $2.03 | $1.98 | $1.99 | 10.12K |
| Jul 27, 2026 | $2.06 | $2.10 | $2.00 | $2.00 | 5.97K |
Latest HIND news
The latest Smart Investors Daily articles mentioning HIND.
Stock researchCompany · Overview
HIND research
Overview
Company profile and research snapshot.
Company profile
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $15.00
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Feb 11, 2026
Vyome Files For Orphan Drug Status For VT-1953, Its Lead Clinical Program
Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&D tax benefits, and PDUFA fee waiver of approximately $3MIndependent third-party assessment estimates a current VT-1953
Benzinga · Feb 4, 2026
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · Feb 2, 2026
Vyome Capitalizes VT-1953 Phase 3 Interim Results By Raising $5.29M Through Sale Of 1,089,045 Shares At $5.00
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
